SinoMab BioScience Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	-	2.03	1.37	-	25.91
Other Revenue	-	-	-	4.03	0.74
Revenue	-	2.03	1.37	4.03	26.66
Revenue Growth (YoY)	-	48.43%	-66.15%	-84.88%	108.91%
Cost of Revenue	-	1.48	0.94	-	-
Gross Profit	-	0.54	0.42	4.03	26.66
Selling, General & Admin	46.38	67.72	97.62	82.59	133.4
Research & Development	81.62	94.75	135.41	180.37	199.11
Operating Expenses	128.01	162.47	233.02	262.96	332.51
Operating Income	-128.01	-161.93	-232.6	-258.93	-305.86
Interest Expense	-5.53	-8.66	-6.58	-4.96	-5.82
Interest & Investment Income	3.71	5.88	6.18	9.58	16.73
Earnings From Equity Investments	-	-	-	-5.4	-4.29
Currency Exchange Gain (Loss)	11.39	-9.47	-12.81	-61.89	9.88
Other Non Operating Income (Expenses)	6.13	1.53	3.74	0.59	1.16
EBT Excluding Unusual Items	-112.3	-172.65	-242.08	-321.01	-288.19
Gain (Loss) on Sale of Investments	-	-	-	39.77	-
Gain (Loss) on Sale of Assets	-0.09	0.08	-	-1.44	-
Asset Writedown	-	-	-	-1.48	-
Other Unusual Items	7.41	-12.58	-1.03	-	-
Pretax Income	-104.99	-185.14	-243.11	-284.16	-288.19
Earnings From Continuing Operations	-104.99	-185.14	-243.11	-284.16	-288.19
Net Income	-104.99	-185.14	-243.11	-284.16	-288.19
Net Income to Common	-104.99	-185.14	-243.11	-284.16	-288.19
Shares Outstanding (Basic)	1,227	1,074	1,018	992	995
Shares Outstanding (Diluted)	1,227	1,074	1,018	992	995
Shares Change (YoY)	14.30%	5.46%	2.64%	-0.29%	-1.13%
EPS (Basic)	-0.09	-0.17	-0.24	-0.29	-0.29
EPS (Diluted)	-0.09	-0.17	-0.24	-0.29	-0.29
Free Cash Flow	-70.48	-171.97	-237.19	-413.29	-345.3
Free Cash Flow Per Share	-0.06	-0.16	-0.23	-0.42	-0.35
Gross Margin	-	26.80%	30.92%	100.00%	100.00%
Operating Margin	-	-7992.40%	-17040.44%	-6421.80%	-1147.38%
Profit Margin	-	-9138.25%	-17810.33%	-7047.57%	-1081.12%
Free Cash Flow Margin	-	-8487.96%	-17376.19%	-10250.22%	-1295.33%
EBITDA	-113.15	-147.07	-213.47	-244.29	-296.43
D&A For EBITDA	14.86	14.86	19.13	14.63	9.43
EBIT	-128.01	-161.93	-232.6	-258.93	-305.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.